Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece.

Kousoulakou, Hara; Hatzikou, Magdalini; Baroutsou, Varvara; Yfantopoulos, John

Kousoulakou, Hara; Hatzikou, Magdalini; Baroutsou, Varvara; Yfantopoulos, John.

Afiliação

Kousoulakou H; University of Peloponnese, Damaskinou & Kolokotroni, 20100 Corinth, Greece.
Hatzikou M; Novartis Hellas SACI, National Rd, No 1, 12th km, Metamorphosis, 14451 Athens, Greece.
Baroutsou V; Novartis Hellas SACI, National Rd, No 1, 12th km, Metamorphosis, 14451 Athens, Greece.
Yfantopoulos J; National and Kapodistrian University of Athens, 45 Akadimias, 10672 Athens, Greece.

Cost Eff Resour Alloc ; 15: 19, 2017.

Article em En | MEDLINE | ID: mdl-28904527

Palavras-chave

Cost-effectiveness; Greece; Type 2 diabetes mellitus; Vildagliptin

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: Cost Eff Resour Alloc Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Grécia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google